Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Study Details New Molecular Approach to Preventing Alzheimer's

The concept calls for targeting an enzyme within brain cells

By Ed Edelson
HealthDay Reporter


Related Encyclopedia
 border=
Acoustic Neurinoma
Alzheimer's Disease
Bell's Palsy
Brain and Spinal Cord Magnetic Resonance Imaging
More...

Related Healthscout Videos
 border=
The On-X Valve PROACT Trial
The On-X Heart Valve: Longevity With Less Reliance on Coumadin
Tissue Valves vs. Mechanical Valves
What is the difference between heart valve repair and replacement?
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Erectile Dysfunction
What is a Heart Attack?
More...

Related Drug Information
 border=
Actonel
Adderal XR
Concerta
Coumadin
More...

Related News Articles
 border=
Larger Men at Greater Risk for Atrial Fibrillation
Flu Strikes a Milder Blow This Season
FDA Panel Snubs Seroquel as 1st Choice Depression Treatment
Where is the Wisdom?
More...

THURSDAY, April 24 (HealthDay News) -- German researchers are reporting a new approach to the possible prevention of the molecular "debris" that's associated with the development of Alzheimer's disease.

The basic idea -- to block the activity of an enzyme called beta-secretase -- is not new, said study lead author Dr. Kai Simons, a professor of cell biology at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden.

Text Continues Below



A number of laboratories, both academic and commercial, are working on methods to prevent the enzyme from slicing a protein into beta amyloid fragments that form the brain plaques found in people with the disease. All work on the same principle. "If we decrease the amount of cleavage, we could in all likelihood reduce the likelihood of the disease," Simons said.

Most experts now agree that formation of the beta amyloid plaques is directly linked to the development of Alzheimer's. The problem with most proposed methods of blocking beta-secretase, Simons said, is that they are designed to work outside of the affected brain cells.

"This process of cleaving takes place inside cells," he said. "We have constructed an inhibitor which binds outside, on the cell membrane, and goes into the cell where the cleavage occurs."

Reporting in the April 25 issue of the journal Science, Simons and his colleagues described both test-tube experiments and animal studies in which the combination of an anchoring molecule and a beta-secretase inhibitor reduced the formation of beta amyloid plaque by more than 50 percent over four hours, while the inhibitor alone was ineffective.

The success is just one small step toward a medically useful preventive therapy for Alzheimer's disease, Simons acknowledged. For one thing, the treatment was given by injection into the brains of the experimental animals (fruit flies and mice), something not likely to be done with people.

Page:  1 | 2 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 4/24/2008

Related Links
 border=
From Healthscout's partner site on alzheimer's disease, OurAlzheimers.com
I need to know about Alzheimer's symptoms.
What are the stages of Alzheimer's Disease?
Learn about Alzheimer's medications.





SOURCES: Kai Simons, M.D., Ph.D., professor of cell biology, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany; William J. Netzer, Ph.D., research associate, Fisher Center for Alzheimer's Disease Research Foundation, Rockefeller University, New York City; James Galvin, M.D., associate professor of neurology and psychiatry, Washington University, St. Louis; April 25, 2008, Science


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map